From the Middle East and North Africa to China for Medical Care: Government Programs, Insurance Pathways, Costs, and a Decision Framework

Reading time: 18 minutes

Patients from the Middle East and North Africa (MENA) have been travelling abroad for healthcare for decades. Saudi Arabia’s Ministry of Health established its Treatment Abroad Program in 1991, covering complex conditions for Saudi nationals; the UAE’s Daman and Thiqa national insurance schemes and Qatar’s Hamad Medical Corporation all maintain overseas referral channels [1][2][3][4]. Historically the main destinations for MENA patients have been Germany (cardiac, oncology, transplant), the UK (oncology, complex surgery), the US (rare diseases, advanced therapies), Thailand (cardiac, check-ups), India (cost-effective cardiac and orthopaedic), and Turkey (transplant, cosmetic).

China is a newer entrant — but growing fast. Several reasons sit behind this:

Belt and Road economic ties have deepened links between China and MENA — Saudi Arabia, the UAE, Egypt, and Qatar have all seen significant trade and investment growth with China over the past five years, with healthcare emerging as a follow-on field.
CAR-T cell therapy and proton/heavy-ion therapy — China has six NMPA-approved CAR-T products at roughly 1/4 the U.S. price; SPHIC and Heyou Pinnacle are among the few centres on the Chinese mainland equipped with both proton and heavy-ion capability [12][13]. These are exactly the therapies where MENA patients face long queues or unaffordable prices in Germany or the U.S.
Pressure on government overseas-treatment budgets — Saudi Treatment Abroad has tightened approvals in recent years, with some “non-essential” cases pushed to self-pay. China’s lower cost relative to Germany or the U.S. has put it onto the candidate list.
GCC mid-to-high-end commercial insurers (Bupa Arabia, Daman international, Tawuniya, AXA Gulf) are actively expanding their China direct-billing networks.
The Lebanese currency collapse and Egyptian devaluation have made traditional destinations (London, Germany) prohibitively expensive in local-currency terms, pushing Asian options onto the table.

But MENA patients coming to China face specific considerations that need to be made explicit upfront: halal food, prayer facilities, female physicians (for female patients), family accompaniment, privacy, treatment scheduling around Ramadan. These aren’t “nice-to-haves” — they are necessary conditions that must be confirmed before travel.

This article helps you decide: does your situation actually warrant looking at China? If so, what’s the pathway, how does it compare to Germany / UK / Thailand / India, and how is cultural fit handled?

1. How healthcare actually works across MENA

MENA is a highly heterogeneous region — there is no single “MENA healthcare.” Three broad categories:

GCC states (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman)

Nationals: government healthcare covers almost everything. Saudi nationals can apply through the Ministry of Health’s Treatment Abroad Program; UAE nationals have Thiqa; Qatari nationals access overseas referral via Hamad. But these government programs have approval criteria — typically “the treatment is unavailable domestically” or “the wait is excessive and the condition is life-threatening.” Routine elective surgery, self-selected destinations, and acceleration of timing — generally not covered.
Foreign residents (a large share of the GCC population is expat): covered through employer commercial insurance (Bupa Arabia, Daman, AXA Gulf, GIG Gulf) or self-pay.
GCC premium commercial insurance (Bupa Gold/Platinum, Daman Premium) typically covers some overseas elective treatment, but with destination restrictions, pre-authorization requirements, and annual caps.

Levant (Lebanon, Jordan, Palestinian Territories, Iraq)

Lebanon: post-currency-collapse the medical system has materially degraded; public hospital drug supply is unstable; the middle class faces a scissors effect — medical costs priced in USD against incomes paid in devalued LBP.
Jordan: regional medical hub; Amman private hospitals (King Hussein Cancer Center, Jordan Hospital) serve Iraqi, Syrian, and Palestinian patients, but costs are now high-end by regional standards.
Iraq: public system in reconstruction; affluent families typically travel to Turkey, Jordan, or India.

North Africa (Egypt, Morocco, Algeria, Tunisia)

Egypt: large but congested public system; private hospitals (Cleopatra Hospital, Andalusia Group) serve the upper-middle class; currency pressure is shifting families that historically went to Europe toward more affordable destinations.
Morocco, Tunisia: strong ties to French medicine; historically travel to France for treatment; increasingly looking at Asia.
Algeria: government partial coverage of overseas; traditional destinations France and Turkey.

The common “look abroad” logic across MENA

MENA patients’ drivers for overseas care differ fundamentally from those of UK or U.S. patients:

It’s not a queueing problem: GCC nationals at KFSH&RC, Hamad, or Cleveland Clinic Abu Dhabi generally see a specialist quickly.
It’s not a basic-care problem: top GCC public hospitals (KFSH&RC, Hamad, SKMC) deliver clinical quality on par with Europe or the U.S.
It IS an access problem for specific advanced therapies: what’s not done locally, what you can’t wait for locally, or what isn’t on the government coverage list locally.
It IS a cost problem (middle class, non-GCC countries): when traditional destinations (London, Germany) are no longer manageable.
It IS a second-opinion-and-plan-confirmation problem: for complex cases where international multi-perspective validation matters.

2. Situations where “look at China” is a reasonable decision (MENA edition)

🟢 Situations that suit a China pathway

🟢 Advanced therapies — cost and access

CAR-T cell therapy: U.S. list price $400K+, Germany €300K+, UK private £350K+. China has six NMPA-approved CAR-T products, all-inclusive USD $160K–$220K (including hospitalisation and complications). Saudi, UAE, and Qatari nationals can typically access U.S. or European treatment through government programs, but approval may take months; self-pay patients choosing China save 60%+.
Proton and heavy-ion therapy: Germany, Switzerland, the U.S., and Japan are traditional destinations at €80K–€200K per course. China’s SPHIC (public) costs $30K–$50K; Heyou Pinnacle (private, proton + heavy-ion) is available case-by-case. MENA has no currently operating heavy-ion centre — Egypt’s planned Alexandria proton centre is not yet operational; Saudi KFSH’s proton plan is under construction.
Certain NMPA-approved drugs not yet approved in Europe or the U.S. — relevant in a small number of cases.

🟢 vs traditional destinations on price pressure

Lebanese, Egyptian, and Jordanian middle-class families can no longer absorb European self-pay bills from London, Paris, or Berlin.
China’s all-inclusive USD pricing is more controllable in FX terms — all fees settle in USD, insulated from non-GCC currency volatility (the Saudi riyal and UAE dirham are USD-pegged).
India’s traditional value-for-money advantage remains, but China runs deeper clinical depth in specific advanced therapies (CAR-T, proton+heavy-ion, complex neurointervention).

🟢 Second opinion and plan confirmation

Pressure-test a local diagnosis and treatment plan with an international MDT.
Oncology, cardiac surgery, complex neurosurgery decisions.
China has globally leading treatment experience in liver cancer, gastric cancer, nasopharyngeal cancer — particularly relevant given MENA’s higher liver cancer incidence; China is a high-value referral destination.

🟢 Premium executive physicals and early-cancer screening

Comprehensive packages completed in 3–5 days, including PET-CT, high-field MRI, ultrasound, endoscopy, full tumour marker panels.
USD $2,500–$9,500 (public IMD to private international) — meaningful advantage over Germany €5K–€15K or the U.S. $5K–$15K.

🟢 GCC high-net-worth multi-destination strategies

Families already accustomed to specific treatments in Europe or the U.S. now bring China into the “comparative quote” phase.
For certain treatments (CAR-T, proton+heavy-ion, complex neurosurgery) China is the most cost-effective option; for others, Europe or the U.S. remains the choice.
Dual-track use of China and Western destinations is increasingly common in GCC high-end patient practice.

🟢 China–MENA cross-border families

Family members working, studying, or doing business in China (Belt and Road corridor).
Bilateral care and bilateral remote follow-up.

🔴 Situations that don’t suit China

Emergencies and critical illness — heart attack, stroke, major trauma, uncontrolled infection, severe bleeding. Handle locally or nearby. Crossing borders is itself the medical risk.
Unstable patients who can’t fly long-haul — fit-to-fly must be assessed by your existing treating physician.
You’re already established at Charité, Heidelberg, Hannover (Germany), Royal Marsden, HCA London (UK), or Mayo, Cleveland, MD Anderson (US) with treatment progressing well and no specific reason to switch paths.
Expecting “a miracle cure” — if European or U.S. top-tier oncology centres have called your case untreatable, “China must have something” is usually disappointment in waiting.
Price as the sole driver, willing to accept quality risk — India is cheaper for certain procedures (cardiac, orthopaedic); Thailand is cheaper for others (gender-affirming, cosmetic). China’s edge is complex internal medicine, oncology, advanced therapies — not absolute lowest price.
Cultural and dietary requirements exceed hospital capacity — partner hospitals can provide halal-prepared meals, prayer arrangements, and female-physician matching where possible, but if your standard requires fully halal-certified hospital kitchens, Bumrungrad (Thailand) or major Malaysian hospitals may be a better fit.

3. Two systems in China — and a bridge that runs only one way

The part MENA patients most often misunderstand.

Chinese hospitals fall into two distinct systems:

Public Tier-3A hospitals

Tier-3A is the top rank in China’s hospital classification — equivalent to Charité Berlin, Imperial College London, or Mayo Clinic-tier academic teaching hospitals.
Examples: Peking Union Medical College Hospital, Beijing Tiantan Hospital, Shanghai Ruijin, Fudan-Zhongshan, Sun Yat-sen Memorial in Guangzhou.
Strengths: concentration of senior specialists, very high surgical volumes, can handle the most complex cases, costs are 30–50% of private international and 15–25% of Germany.
Weaknesses: limited English in general wards (interpretation needed; Arabic support typically requires advance booking of an Arabic-speaking concierge), queue logic built around domestic patient flow, inpatient wards utilitarian rather than hotel-grade, halal meals require advance arrangement (Peking Union, Shanghai Huashan, Fudan-Zhongshan and others can accommodate, but it isn’t default).
The International Medical Department (IMD) is the dedicated bilingual channel inside top Tier-3A hospitals — Peking Union, West China, Ruijin, Huashan, Zhongshan all run IMDs designed for international patients and can accommodate halal dietary and prayer needs.

Private international hospitals

Examples: United Family Healthcare (Beijing/Shanghai/Guangzhou), Shanghai Jiahui International Hospital, Heyou Pinnacle Medical Center (Foshan-Shunde, founded by the founder of Midea Group with combined system investment of over RMB 10 billion), Concord Medical’s Guangzhou Concord Cancer Center (proton therapy operational from late 2024).
Strengths go beyond service: fluent English, comprehensive insurance direct billing, hotel-style rooms, on-time appointments, transparent international workflow, better accommodation of halal meals (some hospital kitchens have dedicated halal sections), prayer rooms or multi-faith spaces, higher flexibility for family accompaniment (MENA families typically travel with multiple family members), and greater flexibility in female-physician matching.
A small number of leading private hospitals also run equipment that matches or surpasses most public hospitals — Heyou Pinnacle’s affiliated Heyou Proton & Heavy Ion Center is led by Professor Lu Jiade, who established the clinical technology system at Shanghai SPHIC [13], making it one of the few proton-and-heavy-ion-capable centres on the Chinese mainland. Guangzhou Concord Cancer Center became South China’s first operating private proton therapy centre in late 2024.
Physician composition: the overwhelming majority of China’s top specialists remain in public Tier-3A, but a smaller cohort of senior physicians have moved part-time or full-time into private hospitals. Heyou Pinnacle is the clearest case in point — beyond Lu Jiade, the group has attracted Li Baomin (national pioneer in neurointervention, 20,000+ stent placement and embolisation cases), Su Fengxi (Honorary President of Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital, over 10,000 breast cancer surgeries), and other senior specialists.
Shared weakness: the most complex, specialty-defining procedures (top oncology, complex cardiac, complex neuro, transplant) — public Tier-3A remains the primary route.

⚠️ The one-way bridge — the rule you can’t afford to get wrong

✅ Public → Private works. A diagnosis, imaging report, or prescription issued by a public Tier-3A hospital is recognised by private international hospitals.
❌ Private → Public does not. A private hospital’s consultation, imaging interpretation, or treatment plan is generally not accepted by a public Tier-3A as the basis for surgery or admission.

The reason: public Tier-3A is the higher-ranked tier in the Chinese medical hierarchy, and the downstream (private) accepts the upstream (public), but not vice versa.

What this means for your decision:

Complex cases (top oncology, complex cardiac, neuro, transplant): stay in the public Tier-3A system end-to-end.
Routine cases (outpatient, imaging, executive physical, IVF, general specialty, dermatology, ophthalmology): stay in private international end-to-end.
The Public → Private follow-up bridge: appropriate for stable patients who’ve completed public treatment and need routine management.
❌ What not to do: assume you can run diagnostics at private and “save money by getting the surgery at public.” You’ll pay for the workup twice.

4. Real cost comparison vs traditional MENA destinations (USD, all at 1 USD = 6.5 RMB)

The table below compares Germany, UK, U.S., Thailand, India, and China — the destinations MENA patients actually consider. All figures are ranges, not commitments.

Procedure	Germany Private	UK Private	U.S. Self-Pay	Thailand (Bumrungrad / BNH)	India (Apollo / Fortis)	China Public IMD	China Private International
Hip replacement	$25K–$40K	£17K–£22K	$40K–$80K	$12K–$18K	$7K–$11K	$8K–$12K	$15K–$22K
Knee replacement	$22K–$35K	£17K–£22K	$35K–$70K	$12K–$18K	$7K–$11K	$8K–$12K	$15K–$22K
Spine fusion	$40K–$70K	£25K–£35K	$80K–$150K	$20K–$30K	$10K–$18K	$12K–$18K	$25K–$35K
Cardiac valve replacement	€30K–€55K	£35K–£55K	$150K–$250K	$25K–$40K	$12K–$20K	$20K–$30K	$40K–$65K
CABG (coronary bypass)	€25K–€40K	£25K–£40K	$75K–$200K	$18K–$28K	$8K–$15K	$20K–$35K	$40K–$70K
Comprehensive checkup (incl. PET-CT)	€5K–€15K	£3.5K–£8K	$5K–$15K	$2K–$5K	$1.2K–$3K	$2.5K–$4.5K	$5.5K–$9.5K
IVF, single cycle	€5K–€10K	£8K–£12K	$15K–$25K	$5K–$9K	$3.5K–$6K	$5K–$8K	$10K–$16K
CAR-T cell therapy	€300K+	£350K+	$400K+ (actual $700K–$1M)	Not performed	Domestic in development	USD $160K–$220K (all-inclusive)	Not performed at private
Proton / heavy-ion therapy	€80K–€150K	£80K–£200K	$80K–$200K	Not available	Very few centres, narrow indications	USD $30K–$50K (SPHIC; proton + heavy-ion)	Heyou Pinnacle (proton + heavy-ion); Guangzhou Concord (proton); case-by-case
Hepatocellular cancer resection	€25K–€45K	£20K–£35K	$50K–$120K	$15K–$25K	$7K–$15K	$12K–$20K	$25K–$40K
Nasopharyngeal cancer (full chemoradiation)	€30K–€60K	£25K–£50K	$80K–$200K	$20K–$35K	$10K–$18K	$15K–$30K	$35K–$60K

Notes on what the table doesn’t show:

China vs India: India retains an edge on cardiac, orthopaedic, and pure cost; China has deeper clinical depth in CAR-T, proton+heavy-ion, complex neurointervention, hepatocellular and nasopharyngeal cancer, with imaging and pathology quality closer to European or U.S. standards.
China vs Thailand: Bumrungrad / Bangkok Hospital have decades of experience serving MENA patients, with mature halal and Arabic-language support. China’s pricing is similar but access to advanced therapies (CAR-T, proton+heavy-ion) is better. For comprehensive check-ups, orthopaedic, or cardiac, Thailand remains a reasonable option.
China vs Germany / UK / U.S.: clinical top-tier quality is comparable, prices are 30–50%, and wait times are 1–2 weeks vs 2–6 weeks (or longer). But MENA patients have decades of network and process familiarity with Germany, the UK, and the U.S. — switching to China requires rebuilding trust and logistics. That’s the work MedCareInChina does.
GCC government overseas programs: Saudi Treatment Abroad, UAE Thiqa, Qatar Hamad overseas referral primarily cover Germany, the U.S., the UK, and Singapore. Coverage of China is still being expanded. Check the latest approved-destination list with your program.

5. Do MENA insurance plans actually work in China?

The honest answer: it depends on your insurance type, your nationality, and whether your insurer has a direct-billing contract with your target hospital.

International medical insurance commonly used by MENA HNW individuals and corporate employers (with substantial China direct-billing networks)

Bupa Global [6] — Expanded in 2025 to 3,600 designated hospitals across 300 cities, covering both public IMDs and private internationals. Bupa Arabia operates in Saudi Arabia, but Bupa Arabia is a regional product; for China direct billing you typically need Bupa Global Premier or a similar international product.
Cigna Global [5] — global network of 1.65M facilities; Shanghai operations center; China direct billing covers both public and private.
AXA Global Healthcare [9] — AXA’s international product. Via Prosper Health partnership, covers approximately 1,350 Tier-3A public hospitals (including PUMCH, Sun Yat-sen, Huashan) plus major private internationals. AXA Gulf (regional) requires separate confirmation.
Allianz Worldwide Care [7] — 280+ public IMD and private international hospitals. Commonly held via GCC corporate employer plans.
MSH International [8] — 500+ hospitals across 20+ cities.
GMMI (Global Medical Management Inc) — common TPA across MENA and Southeast Asia.
William Russell, April International — available through brokers in MENA.

MENA regional insurance and government programs (case-by-case confirmation for China elective)

Daman (UAE Abu Dhabi nationals/residents) — Daman Premier international product covers overseas elective; standard Daman generally does not.
Thiqa (UAE nationals) — government program; overseas elective requires national-level approval.
Tawuniya (Saudi Arabia) — some premium products support overseas elective; confirm item by item.
Bupa Arabia (Saudi Arabia) — premium products support overseas, but destination needs confirmation.
GIG Gulf (Kuwait, Bahrain, Qatar) — premium products support overseas.
Saudi Ministry of Health Treatment Abroad Program — national-level coverage of major illness overseas. Primary destinations currently Germany, U.S., UK, Singapore; China being expanded.
Egyptian, Jordanian, Lebanese state insurance — generally does not cover overseas elective.

Plans that generally won’t work for planned care in China

MENA basic state insurance / government insurance (non-overseas-program portion) — generally does not cover overseas.
Travel insurance — covers sudden illness and accidents only, not planned treatment.

Direct billing vs reimbursement

Direct billing: the insurer pays the hospital directly; you cover only your deductible and copay. The widely repeated claim that “only private international hospitals support direct billing” is out of date — leading public Tier-3A IMDs now run extensive direct-billing networks.

Public IMD	Direct-billing insurers
Shanghai Huashan IMC	30+ direct billing contracts, ~100 actual partnerships; insurance business accounts for over 50% of revenue
Shanghai Ruijin IMD	20+ direct-billing insurers (since 1998)
Peking Union (PUMCH) IMS	Maintains a full “Cooperative Commercial Insurance Roster” including major international insurers
Sun Yat-sen 1st Affiliated Hospital Nansha IMC	15 commercial insurers (opened 2023)

Private international hospital	Direct-billing insurers
Shanghai Jiahui International Hospital	~60 global insurers (broadest in East China)
Shanghai ParkwayHealth / SIMC	50+ direct billing; SIMC 60+ global partners
United Family Healthcare (Beijing/Shanghai/Guangzhou/Shenzhen/Boao)	22 international insurers
Heyou Pinnacle Medical Center (Foshan-Shunde)	Supports international commercial insurance direct billing; designated institution under the GBA “HK/Macao Drug & Device Access” policy

Reimbursement (when direct billing isn’t available): you pay out of pocket, then claim back home. Almost all international policies accept this, but you’ll need:

English / Arabic-translated medical records, itemised bills, and the Chinese tax invoice (Fapiao).
Pre-authorisation filed with your insurer in advance.
Treatment falling within your policy scope.
A 4–12 week processing window.

What we can do, and what we don’t

⚠️ MedCareInChina is not an insurance company. We do not negotiate with your insurer on your behalf, and we do not advance insurance funds.

What we can do:

Help you confirm coverage scope and in-network hospitals with your insurer.
Help you prepare pre-authorisation packages.
Coordinate direct-billing communication and GOP applications.
After discharge, organise English-language medical records, bills, and payment receipts for your reimbursement claim back home.
Help prepare hospital acceptance letters and treatment budget documents for Saudi Treatment Abroad, UAE Thiqa, and similar government programs (final approval rests with the government program, not with us).

What we don’t do:

Make insurance or government-program decisions for you.
Promise insurer or government-program approval.
Hold or pass through insurance/government funds.

6. The five steps of going from MENA to China for care

Total elapsed time from your first email to your return flight is roughly 6–12 weeks (not counting treatment itself).

Step 1 · Free Pathway Scan (1–2 business days)

Email us with:

Your current condition or diagnostic direction
Your country and city, and a rough travel window
Your insurance situation (GCC government program, commercial insurance, international insurance, self-pay)
A description of your records
Any cultural or dietary requirements (halal, female physician, number of family members travelling, Ramadan timing considerations)

We reply with: whether it’s worth continuing + recommended next step + additional records to gather + pre-confirmed feasibility of halal meals, prayer arrangements, and family accommodation at candidate hospitals. Free, no commitment.

Step 2 · Remote Expert / MDT Consultation (5–10 business days, paid)

Single Expert: USD $800 flat.
MDT: USD $1,000 per specialist (typical MDT = 3 specialists = $3,000).
Records translated → Chinese case brief → specialist matching → video consultation → English + Chinese bilingual PDF report (Arabic translation available on request, advance notice needed).

Take the report back to your local physician for discussion. You can also stop here.

Step 3 · S2 Medical Visa (2–4 weeks)

S2 visa [15][19]: medical treatment ≤6 months. Requires Chinese-hospital-issued invitation letter.
S1 visa: medical treatment >6 months, allows accompanying family.
L visa (tourist): not recommended for sustained treatment.

⚠️ MedCareInChina does not process visas. We coordinate the invitation letter; you submit the visa application at:

Saudi Arabia: Chinese Embassy in Riyadh, Consulate in Jeddah, via CVASC Riyadh / Jeddah
UAE: Chinese Embassy in Abu Dhabi, Consulate in Dubai, via CVASC Abu Dhabi / Dubai
Qatar: Chinese Embassy in Doha
Egypt: Chinese Embassy in Cairo, Consulate in Alexandria
Lebanon: Chinese Embassy in Beirut
Jordan: Chinese Embassy in Amman
Other countries: see the Chinese embassy/consulate website for your country

Invitation letter: 5–10 business days. CVASC standard processing: 4–7 business days. Expedited available.

Step 4 · In-China Accompanied Care (during treatment)

Airport pickup, appointment coordination, medical interpretation (English; Arabic via city- and hospital-specific Arabic-speaking concierge arrangements), payment coordination, insurance documentation support, English-language discharge files, hand-off to your local physician.
Halal meal arrangements: partner hospitals (including PUMCH IMS, Huashan IMC, Heyou Pinnacle, United Family, Jiahui) can all accommodate halal meal preparation.
Prayer arrangements: most top Tier-3A and private international hospitals have multi-faith spaces or can coordinate quiet space.
Family accommodation: assistance in coordinating serviced apartments near the hospital, suitable for multiple family members on extended stays.
Female-physician matching: certain specialties (obstetrics, breast, orthopaedic) can prioritise female physicians, but we cannot guarantee a female-physician option in every specialty.
Ramadan considerations: surgical schedules, medication timing, and exam windows can be coordinated with the hospital around Iftar/Suhoor.

Typical durations: hip/knee replacement 2–3 weeks; cataract 3–4 days; checkup 3–5 days; CAR-T full course 4–6 weeks; proton therapy 4–8 weeks.

Fee structure:

Consultation fee (Step 2): paid to MedCareInChina.
Accompaniment service fee: stated in writing before you sign.
Hospital and physician fees: paid directly to the hospital. MedCareInChina does not handle medical funds.
Hotel, flights, transport: you arrange and pay directly.

Step 5 · Remote follow-up after returning home

Chinese attending physician schedules remote follow-up (video).
We continue coordinating communication between the Chinese hospital and your local physician.
For insurance or government-program supplementary documentation, we continue providing English / Arabic materials.
For any emergency, seek local emergency care immediately.

7. When you shouldn’t consider China

You’re currently admitted in a local hospital and unstable.
You’re already established at a top German, UK, or U.S. centre with treatment progressing well.
You’re hoping “China must have something” for late-stage disease European or U.S. top-tier oncology has called untreatable.
Price is your only driver — India or Thailand may be more cost-optimal.
You can’t accommodate a 6–12 week process.
Your insurance or government program doesn’t cover China and self-pay exceeds your budget.
Your cultural or dietary requirements exceed hospital capacity (e.g., requirement for fully halal-certified hospital kitchens — most Chinese hospitals can prepare halal meals but are not certified as halal-only kitchens).

8. Frequently asked, honestly answered

Q: Can I use Saudi Treatment Abroad / UAE Thiqa for treatment in China?
Currently Saudi Ministry of Health Treatment Abroad primarily approves Germany, the U.S., the UK, and Singapore; China is being expanded. Confirm directly with the Ministry or Thiqa whether your specific diagnosis can be approved for China as the destination. We can help provide the Chinese hospital’s acceptance letter, treatment plan, and cost budget documents required by the government program, but final approval rests with the program.

Q: Can halal meals be guaranteed?
Our partner hospitals (PUMCH IMS, Huashan IMC, Heyou Pinnacle, United Family, Jiahui) can all accommodate halal-prepared meals. Note: Chinese hospital kitchens are typically not certified as halal-only kitchens; they prepare halal meals on request. If your standard exceeds this (e.g., requiring a halal-certified kitchen section), Bumrungrad (Thailand) or major Malaysian hospitals may be a better fit.

Q: Can female physicians be matched?
Obstetrics, breast, endocrinology and some other specialties typically have female-physician options. Orthopaedic, cardiac, neurosurgery — not always — China’s top surgical specialists remain predominantly male. We prioritise matching by preference, but cannot guarantee a female option in every specialty.

Q: Can family travel with the patient? Where do they stay?
Yes. The S2 visa supports a separate accompanying-family application. MENA families typically travel with multiple family members, and we help coordinate serviced apartments near the hospital. Most Tier-3A IMDs allow one family member to stay overnight in the patient’s room; additional family members can visit during the day.

Q: Is Arabic interpretation available?
English interpretation is standard; Arabic interpretation needs to be booked in advance — typically through Arabic-speaking concierge services at top international hospitals in Beijing, Shanghai, Guangzhou, and Foshan. Flag this during the Pathway Scan so we can confirm availability.

Q: Can I come during Ramadan?
Yes, but it needs to be discussed in advance. Surgical schedules, exam windows, and medication timing can be coordinated around Iftar/Suhoor. For insulin-dependent diabetes, oncology chemotherapy, and other treatments that cannot be interrupted, the treating physician and you should jointly decide on timing.

Q: If something goes wrong during surgery, who’s responsible?
The Chinese hospital. MedCareInChina is not a medical provider, does not make medical decisions, and is not responsible for medical outcomes. See our Terms of Service and Medical Disclaimer [22].

Q: Should I choose public or private in China?
Match-based. Complex specialty-defining cases (oncology, complex cardiac, neuro, transplant) — public Tier-3A. Routine outpatient/imaging/checkup/general specialty — private international. The middle ground is case-by-case work — that’s what we do.

9. Next step — send us your case

📧 hello@medcareinchina.com

Subject: Pathway Scan from [Your Country] (e.g., Pathway Scan from Saudi Arabia / UAE / Egypt)

In the body, tell us:

Your current condition or diagnostic direction (one or two sentences)
Your country and city, rough travel window
Your insurance or government-program situation (insurer name, whether applying through Treatment Abroad / Thiqa, etc., no policy number needed)
The state of your medical records (describe; don’t send files yet)
Any cultural or dietary requirements (halal, female physician, number of family members, Ramadan timing)

We respond within 1–2 business days with a free written assessment.

This step is always free. No payment, no commitment, no follow-up marketing emails.

Sources

[1] Saudi Ministry of Health · Treatment Abroad Program — Official Saudi national overseas-treatment program. https://www.moh.gov.sa/

[2] UAE Daman National Health Insurance — Abu Dhabi national/resident insurance. https://www.damanhealth.ae/

[3] UAE Thiqa Program — UAE national overseas-treatment program.

[4] Qatar Hamad Medical Corporation · International Patient Services — Qatari overseas referral. https://www.hamad.qa/

[5] Cigna Global · International Health Insurance — China direct billing network. https://www.cignaglobal.com/

[6] Bupa Global · Find a Provider — 2025 expansion to 3,600 designated hospitals across 300 cities. https://www.bupaglobal.com/en/customers/find-a-provider

[7] Allianz Worldwide Care · International Medical Insurance — China provider network (280+ hospitals). https://www.allianzcare.com/

[8] MSH International — 500+ hospitals across 20+ cities. https://www.msh-intl.com/

[9] AXA Global Healthcare — Via Prosper Health partnership covers approximately 1,350 Tier-3A hospitals. https://www.axaglobalhealthcare.com/

[10] Bupa Arabia · International Premium — Saudi regional product; overseas coverage to be confirmed. https://www.bupa.com.sa/

[11] MENA Government Healthcare Programs Overview — Comparative reference for Saudi, UAE, Qatar, and Kuwait overseas-treatment programs.

[12] MedCareInChina · CAR-T Cell Therapy in China — Six NMPA-approved CAR-T products + U.S./EU list price comparison. https://medcareinchina.com/car-t-cell-therapy-in-china-six-approved-products-top-centers-pricing-and-comparison-with-western-centers/

[13] Shanghai Proton and Heavy Ion Center (SPHIC) + Heyou Pinnacle Medical Center (Foshan-Shunde) + Guangzhou Concord Cancer Center — Reference for proton and heavy-ion therapy options in China. Heyou Pinnacle’s Heyou Proton & Heavy Ion Center is directed by Professor Lu Jiade, who established the clinical technology system at SPHIC; Guangzhou Concord Cancer Center (Concord Medical Group) launched proton therapy operations in December 2024. https://medcareinchina.com/proton-and-heavy-ion-therapy-in-china-sphic-process-indications-and-comparison-with-us-japan-and-europe/

[14] MedCareInChina · International Medical Insurance and China Hospital Direct Billing — Public IMD direct-billing roster (Huashan ~100, Ruijin 20+, PUMCH, Sun Yat-sen Nansha 15) and private hospital networks. https://medcareinchina.com/international-medical-insurance-and-china-hospital-direct-billing-a-complete-guide-to-coverage-workflow-and-pitfalls/

[15] MedCareInChina · Complete Guide to China Medical Visa (S1/S2). https://medcareinchina.com/complete-guide-to-china-medical-visa-s1-s2-the-first-step-for-international-patients/

[16] Charité Berlin International Patient Services — German destination reference. https://www.charite.de/en/

[17] Bumrungrad International Hospital (Bangkok) — Traditional Thai destination reference. https://www.bumrungrad.com/

[18] Apollo Hospitals India — Traditional Indian destination reference. https://www.apollohospitals.com/

[19] Embassy of the People’s Republic of China · MENA Regional Sites — Official S1/S2 visa information for Saudi, UAE, Qatar, Egypt, Lebanon, and other Chinese diplomatic missions.

[20] CVASC · MENA Locations — Riyadh, Jeddah, Abu Dhabi, Dubai, Cairo and other CVASC centres. https://www.visaforchina.cn/

[21] King Faisal Specialist Hospital & Research Centre (KFSH&RC) — Top Saudi public hospital reference. https://www.kfshrc.edu.sa/

[22] MedCareInChina · Service & Refund Policy / Medical Disclaimer / Privacy Policy. Service & Refund Policy · Medical Disclaimer · Privacy Policy

Last updated 2026-05-30. All USD / EUR / GBP / RMB conversions calculated at 1 USD = 6.5 RMB; actual exchange rate at settlement applies. All medical decisions remain between you and your treating physician. MedCareInChina provides patient navigation services; it is not a medical provider, does not diagnose, does not prescribe, and does not guarantee treatment outcomes.

— MedCareInChina Editorial Team